Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q1 2025 vs. Q4 2024
How the institutions holding Cingulate Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 9 | 1 | 9 | +1 |
| Shares | 90.7K | 5.01K | 131.6K | +45.9K (+53.6%) |
| Value | $447.4K | $25.0K | $566.1K | +$143.7K (+34.0%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Cingulate Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 10,760 | $46.3K | 0.00% |
| Quantum Private Wealth, LLC | 10,000 | $43.0K | 0.02% |
Sold out (1)
Institutions that held Cingulate Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citigroup Inc | 387 | $1.91K |
Not filed for Q1 2025 yet (1)
Institutions that held Cingulate Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| AlphaMark Advisors, LLC | 5,010 | $25.0K |